Genevestigator

Genevestigator is a bioinformatics application built around a curated gene-expression database and a set of tools for analysing how genes behave across tissues, diseases, treatments, genetic backgrounds and other experimental conditions. The service was initiated in January 2004 by scientists associated with ETH Zurich and was subsequently developed and commercialized by Nebion AG. It is intended for researchers in academia and industry who need to interpret large collections of transcriptomic measurements without treating each experiment as an isolated dataset. The platform aggregates transcriptomic data from public repositories and major research projects. Sources described for the database include the Gene Expression Omnibus, ArrayExpress and cancer research datasets such as The Cancer Genome Atlas. Subject to licensing arrangements, the database may also include privately generated gene-expression studies. Genevestigator’s distinguishing contribution is not only the aggregation of measurements, but also the manual curation and quality control of those records. Sample and experiment descriptions are enriched using information from the underlying scientific publications, helping users compare studies that may otherwise use different terminology, platforms or experimental designs. The biomedical version focuses on human, mouse and rat data and covers research areas including oncology, immunology, neurology, dermatology and cardiovascular disease. Its samples include tissue biopsies and cell lines. Researchers can use the platform to examine expression patterns in normal and diseased tissues, compare treatment responses, investigate candidate biomarkers, assess potential drug targets and select experimental models that resemble a biological condition of interest. Genevestigator’s analytical functions are organized around three broad research questions. Condition-search functions help users identify tissues, diseases, treatments or genetic backgrounds that regulate genes of interest. Gene-search functions identify genes that are selectively or characteristically expressed under specified conditions. Similarity-search functions locate genes or conditions with comparable expression patterns. Together, these workflows support exploratory analysis, hypothesis generation, target validation, biomarker discovery, toxicogenomics and the interpretation of molecular biology experiments. The product historically also included a plant version. That version covered model organisms such as Arabidopsis and Medicago as well as crop species including maize, rice, wheat and soybean. Following Nebion AG’s acquisition by Immunai Inc. in July 2021, the plant data was progressively deprioritized as the business concentrated on biopharmaceutical applications. The plant data was reported as being maintained on a separate server for users who retained a license, while the biomedical offering became the principal focus. Genevestigator has been used by researchers across academia and industry, with published material describing a user base of more than 60,000 scientists. The platform’s underlying methods and datasets have also supported a substantial scientific literature, including a foundational publication that has received more than 3,500 citations according to the referenced description. Genevestigator is therefore best understood as a specialized scientific software and data service rather than a consumer-facing brand: its value lies in curated biological data, cross-study comparability and practical analysis tools for transcriptomic research.

Genevestigator originated in the Swiss academic research environment around ETH Zurich. The project began in January 2004 as an effort to make gene-expression information easier to compare and interpret across experiments. Its early work was particularly associated with Arabidopsis and plant microarray research, reflecting the importance of plant genomics in the project’s initial development. The first publications presented Genevestigator as both a reference expression database and a web-based analysis toolbox. The platform expanded from a plant-focused resource into a broader transcriptomics system. Additional work extended the service to mouse and other biomedical datasets, while later versions incorporated human, mouse and rat expression studies. This expansion gave researchers a way to examine gene regulation across tissues, diseases, treatments and genetic backgrounds using a common interface and standardized annotations. A central part of Genevestigator’s development was the creation of a curated database rather than a simple repository mirror. Public datasets from resources such as the Gene Expression Omnibus and ArrayExpress were assembled with data from major research projects, including cancer datasets. Records were quality-controlled, manually reviewed and enriched with sample and experiment information derived from scientific publications. This curation was intended to improve the comparability and practical usefulness of heterogeneous transcriptomic experiments. The software’s analytical model developed around condition searches, gene searches and similarity searches. These capabilities allowed users to move from a gene to the biological conditions in which it is regulated, from a condition to genes that characterize it, or from one expression profile to similar genes and conditions. The resulting workflows supported target discovery, biomarker research, toxicogenomics, disease biology and the selection of experimental models. Nebion AG became the developer and commercializer of Genevestigator, bringing the service from an academic-origin project into a subscription or licensed research platform for academic and industrial users. The product’s scientific profile was reinforced by publications on transcriptome architecture, clustering and visualization, reference-gene identification and web-based analysis of animal and plant transcriptomes. In July 2021, Nebion AG was acquired by Immunai Inc. The change in ownership affected the relative emphasis of the Genevestigator portfolio. The plant version was progressively phased out as attention shifted toward biomedical and biopharmaceutical data. By 2023, plant data was described as being maintained on a separate server for users who still held a license, while the biomedical version remained the principal active focus. The platform’s continuing role is as a specialized resource for interpreting curated transcriptomic data in research and drug-development contexts.

• 2023

  Plant data maintained separately

  [1]Genevestigatoren.wikipedia.org

  The plant data is described as being maintained on a separate server for remaining licensed users while the biomedical offering receives priority.

• 2021

  Nebion acquired by Immunai

  [1]Genevestigatoren.wikipedia.org

  Immunai acquires Nebion AG, after which the Genevestigator business places greater emphasis on biomedical and biopharmaceutical applications.

• 2008

  Genevestigator V3 published

  [1]Genevestigatoren.wikipedia.org

  A publication presents a later version of Genevestigator as a reference expression database for transcriptome meta-analysis.

• 2006

  Expansion to mouse transcriptome analysis

  [1]Genevestigatoren.wikipedia.org

  Research publications document web-based analysis of mouse transcriptomic data through Genevestigator.

• 2004

  Genevestigator project begins

  [1]Genevestigatoren.wikipedia.org

  Scientists from ETH Zurich begin the Genevestigator project as a gene-expression database and analysis toolbox, initially with a strong plant-science orientation.

• 2004

  First Genevestigator publication

  [1]Genevestigatoren.wikipedia.org

  The initial publication describes Genevestigator as an Arabidopsis microarray database and analysis environment.

A curated, cross-study transcriptomics research platform positioned for target discovery, biomarker research, model selection and biological interpretation in academic and biopharmaceutical settings.

• Biomedical transcriptomics platform

  Biomedical Genevestigator

  The biomedical version contains curated gene-expression data for human, mouse and rat. It supports research across oncology, immunology, neurology, dermatology and cardiovascular disease, using samples such as tissue biopsies and cell lines. Researchers can compare expression across diseases, tissues, treatments and genetic backgrounds to investigate targets, biomarkers and experimental models.

• Plant transcriptomics platform

  Plant Genevestigator

  The historical plant version covered model species including Arabidopsis and Medicago and crops such as maize, rice, wheat and soybean. Following the 2021 acquisition of Nebion by Immunai, plant data was phased out as strategic attention moved toward biopharma. The remaining plant data was reported as available on a separate server to users with an applicable license.

• Gene-expression analysis tool

  Condition Search

  Condition Search helps users identify biological or experimental conditions that regulate genes of interest. Search dimensions can include tissues, diseases, treatments and genetic backgrounds, making the tool useful for exploring where and when a gene is active or suppressed.

• Gene-expression analysis tool

  Gene Search

  Gene Search identifies genes that are specifically or characteristically expressed under selected conditions. It can support candidate discovery in disease biology, biomarker research, target identification and the interpretation of tissue- or treatment-specific expression patterns.

• Gene-expression analysis tool

  Similarity Search

  Similarity Search locates genes or biological conditions with expression patterns resembling a user-selected profile. The function helps researchers generate hypotheses about shared biological roles, related disease states, comparable treatments or potentially informative research models.

• 2021

  Change in ownership through Nebion acquisitionM&A

  Background

  Immunai acquired Nebion AG in July 2021, bringing the Genevestigator product under the ownership of a biotechnology company focused on biomedical applications.

  Action taken

  The Genevestigator portfolio was oriented more strongly toward biopharmaceutical and biomedical data, and the plant version was progressively phased out.

  Aftermath

  The biomedical version remained the main focus, while plant data was maintained separately for remaining licensed users.

  Source

1. 1Genevestigatoren.wikipedia.org
2. 2Genevestigator official websitegenevestigator.com